BioSpace News Archive

City of Hope announced plans to build a new comprehensive cancer campus at FivePoint Gateway in Orange County. As part of that plan, it will invest more than $1 billion into the project.

The company will focus on chemoproteomics, which it calls a way of interrogating proteins in living systems. This allows them to identify potential new binding targets on proteins, which will allow the development of small-molecule drugs.

Global Blood Therapeutics, Inc. announced an agreement to sell approximately $200.0 million in shares of its common stock in a registered underwritten public offering.

A recent list of the top 10 most expensive drugs marketed in the United States shows each of them has a list price of more than half a million dollars annually.

CENTOGENE biomarker measures lyso-Gb1 levels in children

Hacarus Inc, the leading provider of lightweight and explainable AI, was awarded the Grand Prize by DS Pharma Animal Health for its innovative AI-enabled technology platform ‘HACARUS.ai’

Regis Technologies, a contract development and manufacturing organization for small molecule active pharmaceutical ingredients, announces a new Solid State Chemistry service.

Premark Pharma announced the completion of a licensing deal with Novartis Pharma AG, granting Premark exclusive worldwide rights to develop and commercialise PMP2207, an ophthalmic ointment formulation, as a potential treatment for blepharitis.

Amarantus Bioscience Holdings, Inc. announced that it has entered into a Letter of Intent with The Alchemist’s Kitchen, a plant-based wellness company marketing the Plant Alchemy brand of health and wellness products, to establish a joint venture for commercialization of hemp based herbal smokable products ‘Herbal Smokes’ in addition to conducting research for cannabinoid derived addiction treatment, including smoking cessation, and other indications such as insomnia.

The Complete Response Letter indicated the company will need to run an “adequate and well-controlled trial to determine whether celiprolol reduces the risk of clinical events in patients with vEDS.”